Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943022 | 0.94 | YTHDC1 (0.77) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL2709651 | 0.94 | YTHDC1 (0.77) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL16549238 | 0.94 | YTHDC1 (0.77) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL2709647 | 0.94 | YTHDC1 (0.77) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL17902888 | 0.93 | YTHDC1 (0.76) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5447191 | 0.93 | YTHDC1 (0.76) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL2945927 | 0.93 | YTHDC1 (0.76) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL17262855 | 0.89 | YTHDC1 (0.72) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL3712640 | 0.87 | YTHDC1 (0.66) | YTHDC1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL28429578 | 0.84 | YTHDC1 (0.69) | YTHDC1ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377925-B | Purine derivatives, preparation method thereof and application thereof in medicines | 四川科伦博泰生物医药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-111377925-A | Purine derivative, preparation method and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | YTHDC1 4523/4885ADORA3 1744/4885ADORA1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.